Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

New MMP inhibitors for use in inflammatory disorders

Sep. 10, 2002

Sumitomo presents novel agents for arthritis and bone disorders

Sep. 9, 2002

Phase I/II results for HuMax-IL-15 in RA

Sep. 6, 2002

AGIX-4207 enters phase II in rheumatoid arthritis

Sep. 5, 2002

Heterocyclic compounds as selective COX-2 inhibitors presented in Barcelona

Sep. 3, 2002

Phase II/III Fibrillex trial cleared by review board

Sep. 2, 2002

Approvable letter for Genelabs Technologies' Prestara, formerly Aslera

Aug. 30, 2002

Synthesis and SAR studies of selective COX-2 inhibitors disclosed by Pacific Corporation

Aug. 30, 2002

Potent and selective MMP inhibitors designed at Pharmacia

Aug. 29, 2002

TACE inhibitors presented by Bristol-Myers Squibb at ACS

Aug. 27, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...